[go: up one dir, main page]

MX345656B - (piridin-4-il)bencilamidas como moduladores alostericos de nachr alfa 7. - Google Patents

(piridin-4-il)bencilamidas como moduladores alostericos de nachr alfa 7.

Info

Publication number
MX345656B
MX345656B MX2013009798A MX2013009798A MX345656B MX 345656 B MX345656 B MX 345656B MX 2013009798 A MX2013009798 A MX 2013009798A MX 2013009798 A MX2013009798 A MX 2013009798A MX 345656 B MX345656 B MX 345656B
Authority
MX
Mexico
Prior art keywords
allosteric modulators
benzylamides
pyridin
nachr
alpha
Prior art date
Application number
MX2013009798A
Other languages
English (en)
Other versions
MX2013009798A (es
Inventor
BOECK Benoît Christian Albert Ghislain DE
Joseph Elisabeth Leenaerts
Gregor James Macdonald
Geert Rombouts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2013009798A publication Critical patent/MX2013009798A/es
Publication of MX345656B publication Critical patent/MX345656B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a derivados de (piridin-4-iI)bencilamidas y sales farmacéuticamente aceptables de estas, procesos para prepararlas, composiciones farmacéuticas que las contienen y su uso en terapia; la invención se refiere en particular a moduladores alostéricos positivos de los receptores nicotínicos de la acetilcolina, teniendo tales moduladores alostéricos positivos la capacidad de incrementar la eficacia de agonistas de los receptores nicotínicos.
MX2013009798A 2011-02-25 2012-02-23 (piridin-4-il)bencilamidas como moduladores alostericos de nachr alfa 7. MX345656B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11155937 2011-02-25
PCT/EP2012/053047 WO2012113850A2 (en) 2011-02-25 2012-02-23 (PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR

Publications (2)

Publication Number Publication Date
MX2013009798A MX2013009798A (es) 2013-09-26
MX345656B true MX345656B (es) 2017-02-08

Family

ID=44259750

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009798A MX345656B (es) 2011-02-25 2012-02-23 (piridin-4-il)bencilamidas como moduladores alostericos de nachr alfa 7.

Country Status (17)

Country Link
EP (1) EP2678315B1 (es)
JP (1) JP5841617B2 (es)
KR (1) KR101851140B1 (es)
CN (1) CN103402983B (es)
AU (1) AU2012219537B2 (es)
BR (1) BR112013021599A2 (es)
CA (1) CA2824350C (es)
CL (1) CL2013002424A1 (es)
EA (1) EA022164B1 (es)
ES (1) ES2563113T3 (es)
IL (1) IL228054A (es)
MX (1) MX345656B (es)
MY (1) MY161236A (es)
SG (1) SG192939A1 (es)
UA (1) UA109803C2 (es)
WO (1) WO2012113850A2 (es)
ZA (1) ZA201306385B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
CN101827836B (zh) 2007-10-18 2014-02-19 詹森药业有限公司 三取代的1,2,4-三唑化合物
KR101564303B1 (ko) 2008-03-19 2015-11-06 얀센 파마슈티카 엔.브이. 니코틴성 아세틸콜린 수용체 조절제로서의 삼치환된 1,2,4-트리아졸
EP2280945B1 (en) 2008-05-09 2014-09-03 Janssen Pharmaceutica, N.V. Trisubstituted pyrazoles as acetylcholine receptor modulators
CN107922426B (zh) 2015-08-19 2021-03-26 安斯泰来制药株式会社 四氢噁庚英吡啶化合物
CN108348510B (zh) 2015-09-17 2022-01-04 圣母大学 针对分枝杆菌感染有用的含有苄胺的杂环化合物以及组合物
CN108689957B (zh) * 2018-07-23 2020-07-03 南京药石科技股份有限公司 一种2r/2s-三氟甲基吗啉及其盐酸盐的制备方法和应用
US20220040158A1 (en) * 2018-09-24 2022-02-10 Astrazeneca Ab Azd0328 dosage regime for treating cognitive impairment
CN113264867A (zh) * 2021-06-08 2021-08-17 安徽星宇化工有限公司 一种顺式2,6-二甲基哌啶的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1913901A (zh) * 2004-02-04 2007-02-14 神经研究公司 作为胆碱能受体调节剂的二氮杂双环芳基衍生物
JPWO2006082952A1 (ja) * 2005-02-01 2008-06-26 武田薬品工業株式会社 アミド化合物
US20080261999A1 (en) * 2005-03-04 2008-10-23 Fionna Mitchell Martin Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists
AU2006290814B2 (en) 2005-09-13 2012-06-07 Janssen Pharmaceutica N.V. 2-aniline-4-aryl substituted thiazole derivatives
JO3019B1 (ar) 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
CN101448825A (zh) * 2006-05-19 2009-06-03 艾博特公司 Cns活性的稠合的双环杂环取代的氮杂双环烷烃衍生物
JP5564251B2 (ja) * 2006-06-29 2014-07-30 キネックス ファーマシューティカルズ， エルエルシー キナーゼカスケードを調節するためのビアリール組成物および方法
BRPI0717306A2 (pt) * 2006-10-25 2014-04-15 Neurosearch As Composto, composição farmacêutica, uso de um composto, e, método de tratamento, prevenção ou alívio de uma doença ou um distúrbio ou uma condição de um corpo de animal vivo.
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
CN101827836B (zh) 2007-10-18 2014-02-19 詹森药业有限公司 三取代的1,2,4-三唑化合物
KR101564303B1 (ko) 2008-03-19 2015-11-06 얀센 파마슈티카 엔.브이. 니코틴성 아세틸콜린 수용체 조절제로서의 삼치환된 1,2,4-트리아졸
WO2009131129A1 (ja) * 2008-04-22 2009-10-29 第一三共株式会社 ５－ヒドロキシピリミジン－４－カルボキサミド化合物
EP2280945B1 (en) 2008-05-09 2014-09-03 Janssen Pharmaceutica, N.V. Trisubstituted pyrazoles as acetylcholine receptor modulators

Also Published As

Publication number Publication date
AU2012219537A1 (en) 2013-07-18
EP2678315B1 (en) 2015-12-16
CN103402983B (zh) 2015-12-23
ES2563113T3 (es) 2016-03-10
IL228054A (en) 2016-06-30
IL228054A0 (en) 2013-09-30
JP2014506587A (ja) 2014-03-17
ZA201306385B (en) 2015-03-25
JP5841617B2 (ja) 2016-01-13
EA201391228A1 (ru) 2013-12-30
KR20140014163A (ko) 2014-02-05
NZ612688A (en) 2015-08-28
SG192939A1 (en) 2013-09-30
KR101851140B1 (ko) 2018-04-23
CA2824350A1 (en) 2012-08-30
HK1189222A1 (zh) 2014-05-30
CL2013002424A1 (es) 2014-03-28
EP2678315A2 (en) 2014-01-01
WO2012113850A2 (en) 2012-08-30
MX2013009798A (es) 2013-09-26
UA109803C2 (xx) 2015-10-12
EA022164B1 (ru) 2015-11-30
AU2012219537B2 (en) 2016-07-28
CA2824350C (en) 2019-07-02
MY161236A (en) 2017-04-14
BR112013021599A2 (pt) 2016-11-16
CN103402983A (zh) 2013-11-20
WO2012113850A3 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
JO3078B1 (ar) مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
MX345656B (es) (piridin-4-il)bencilamidas como moduladores alostericos de nachr alfa 7.
EA201071288A1 (ru) Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина
MY152486A (en) Trisubstituted 1,2,4 - triazoles as nicotinic acetylcholine receptor modulators
UA114906C2 (uk) Гетероциклільні сполуки як інгібітори мек
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
MX354102B (es) Derivados de bencimidazol-prolina.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
UA109010C2 (en) Morpholino pyrividines and their use in therapy
PH12015501609A1 (en) Phenicol antibacterials
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MX347280B (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos b2 y como antagonistas muscarinicos m3.
EA201270428A1 (ru) Замещенные n-фенил-1-(4-пиридинил)-1н-пиразол-3-амины
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
TN2013000462A1 (en) Positive allosteric modulators of nicotinic acetylcholine receptor
PH12013500004A1 (en) Fused heterocyclic derivatives as s1p modulators
PH12015502632A1 (en) Cxcr7 receptor modulators
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
MY166463A (en) Positive allosteric modulators of nicotinic acetylcholine receptor
IN2015DN02109A (es)
HK1219723A1 (zh) 作为前动力蛋白受体调节剂的派啶和氮杂䓬衍生物
MX2014004742A (es) Nuevos agentes antibacterianos de fenicol.
TN2011000588A1 (en) Novel pharmaceutically acceptable salts of 4-(1h-imidazol-4-ylmethyl) pyridine and their therapeutical uses

Legal Events

Date Code Title Description
FG Grant or registration